CN110272417B - 2-甲基-1,8-萘啶类化合物及其制备方法与应用 - Google Patents
2-甲基-1,8-萘啶类化合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN110272417B CN110272417B CN201910524507.XA CN201910524507A CN110272417B CN 110272417 B CN110272417 B CN 110272417B CN 201910524507 A CN201910524507 A CN 201910524507A CN 110272417 B CN110272417 B CN 110272417B
- Authority
- CN
- China
- Prior art keywords
- methyl
- naphthyridine
- compound
- group
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 2-methyl-1, 8-naphthyridine compound Chemical class 0.000 title claims abstract description 69
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 24
- 239000001257 hydrogen Substances 0.000 claims abstract description 24
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 12
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims abstract description 8
- 125000002541 furyl group Chemical group 0.000 claims abstract description 8
- 125000005059 halophenyl group Chemical group 0.000 claims abstract description 8
- 125000006501 nitrophenyl group Chemical group 0.000 claims abstract description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims abstract description 8
- 125000003373 pyrazinyl group Chemical group 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims description 44
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 34
- 239000012043 crude product Substances 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 14
- 238000004440 column chromatography Methods 0.000 claims description 14
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 230000011987 methylation Effects 0.000 claims description 10
- 238000007069 methylation reaction Methods 0.000 claims description 10
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- FSWRUYCICUXURT-UHFFFAOYSA-N 2-methyl-1,8-naphthyridine Chemical class C1=CC=NC2=NC(C)=CC=C21 FSWRUYCICUXURT-UHFFFAOYSA-N 0.000 claims description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 239000012022 methylating agents Substances 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 230000004071 biological effect Effects 0.000 abstract description 8
- 229910052751 metal Inorganic materials 0.000 abstract description 5
- 239000002184 metal Substances 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 239000003054 catalyst Substances 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- 230000007613 environmental effect Effects 0.000 abstract description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 42
- 238000001228 spectrum Methods 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 29
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 20
- 229910052799 carbon Inorganic materials 0.000 description 20
- 238000000132 electrospray ionisation Methods 0.000 description 20
- 238000004896 high resolution mass spectrometry Methods 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 15
- 238000001914 filtration Methods 0.000 description 12
- 238000001816 cooling Methods 0.000 description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 238000012512 characterization method Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 229940125782 compound 2 Drugs 0.000 description 8
- 238000010025 steaming Methods 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 7
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 5
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- QRDAPCMJAOQZSU-KQQUZDAGSA-N (e)-3-[4-[(e)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-n-hydroxyprop-2-enamide Chemical compound C1=C(\C=C\C(=O)NO)N(C)C=C1\C=C\C(=O)C1=CC=CC(F)=C1 QRDAPCMJAOQZSU-KQQUZDAGSA-N 0.000 description 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 4
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 4
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 4
- REDUQXCPUSNJOL-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O Chemical compound C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O REDUQXCPUSNJOL-UHFFFAOYSA-N 0.000 description 4
- CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 4
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 4
- KSCRVOKQPYZBHZ-IXPOFIJOSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@H]1C(NCC1)=O)C(=O)C=1SC2=CC=CC=C2N=1)C(C)C)C(=O)OCC1=CC=CC=C1 KSCRVOKQPYZBHZ-IXPOFIJOSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 4
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- PHSQDVKDFKUGBJ-UHFFFAOYSA-N 2-(1-benzothiophen-2-yl)-7-methyl-1,8-naphthyridine Chemical compound S1C2=C(C=C1C1=NC3=NC(=CC=C3C=C1)C)C=CC=C2 PHSQDVKDFKUGBJ-UHFFFAOYSA-N 0.000 description 3
- GLGSJUPBYSFUJQ-UHFFFAOYSA-N 2-(3-methoxyphenyl)-7-methyl-1,8-naphthyridine Chemical compound COC=1C=C(C=CC=1)C1=NC2=NC(=CC=C2C=C1)C GLGSJUPBYSFUJQ-UHFFFAOYSA-N 0.000 description 3
- OANBXAMLGXSZBD-UHFFFAOYSA-N 2-(4-bromophenyl)-3,7-dimethyl-1,8-naphthyridine Chemical compound BrC1=CC=C(C=C1)C1=NC2=NC(=CC=C2C=C1C)C OANBXAMLGXSZBD-UHFFFAOYSA-N 0.000 description 3
- BGLSJWRWFABGNC-UHFFFAOYSA-N 2-methyl-7-phenyl-1,8-naphthyridine Chemical compound N=1C2=NC(C)=CC=C2C=CC=1C1=CC=CC=C1 BGLSJWRWFABGNC-UHFFFAOYSA-N 0.000 description 3
- HGBJCDNXNFHCNP-UHFFFAOYSA-N 5,6-dihydronaphthalen-2-ol Chemical compound C1CC=CC2=CC(O)=CC=C21 HGBJCDNXNFHCNP-UHFFFAOYSA-N 0.000 description 3
- MNKJONOHHLSPBN-UHFFFAOYSA-N CC1=CC=C2C=CC(=NC2=N1)C=1SC=CN=1 Chemical compound CC1=CC=C2C=CC(=NC2=N1)C=1SC=CN=1 MNKJONOHHLSPBN-UHFFFAOYSA-N 0.000 description 3
- GCCSQLNGNXYSKA-UHFFFAOYSA-N CC1=NC2=C(C=C1)C=CC(=N2)C3=NC=CN=C3 Chemical compound CC1=NC2=C(C=C1)C=CC(=N2)C3=NC=CN=C3 GCCSQLNGNXYSKA-UHFFFAOYSA-N 0.000 description 3
- UQVGIUJPAKWOSQ-UHFFFAOYSA-N CC1=NC2=NC(=CC=C2C=C1)C1=CC=C(C=C1)C(F)(F)F Chemical compound CC1=NC2=NC(=CC=C2C=C1)C1=CC=C(C=C1)C(F)(F)F UQVGIUJPAKWOSQ-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- HEBAAFXEWATJQY-UHFFFAOYSA-N O1C(=CC=C1)C1=NC2=NC(=CC=C2C=C1)C Chemical compound O1C(=CC=C1)C1=NC2=NC(=CC=C2C=C1)C HEBAAFXEWATJQY-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- VPMIAOSOTOODMY-KJAPKAAFSA-N (4r)-6-[(e)-2-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1/C=C/C=1C(C(C)C)=NC(C(C)(C)C)=CC=1C1=CC=C(F)C=C1 VPMIAOSOTOODMY-KJAPKAAFSA-N 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101100291385 Drosophila melanogaster p38a gene Proteins 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 2
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 150000005058 1,8-naphthyridines Chemical class 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- GADKBDXTPNAVLF-UHFFFAOYSA-N 2-(1,8-naphthyridin-2-yl)-1,3-thiazole Chemical compound C1=CSC(C=2N=C3N=CC=CC3=CC=2)=N1 GADKBDXTPNAVLF-UHFFFAOYSA-N 0.000 description 1
- LRZMNDPVLPQMRJ-UHFFFAOYSA-N 2-(3-methoxyphenyl)-1,8-naphthyridine Chemical compound COC=1C=C(C=CC=1)C1=NC2=NC=CC=C2C=C1 LRZMNDPVLPQMRJ-UHFFFAOYSA-N 0.000 description 1
- ZGMVYQNGMZUBGJ-UHFFFAOYSA-N 2-(4-bromophenyl)-3-methyl-1,8-naphthyridine Chemical compound BrC1=CC=C(C=C1)C1=NC2=NC=CC=C2C=C1C ZGMVYQNGMZUBGJ-UHFFFAOYSA-N 0.000 description 1
- WTMHWTWJFMWWGI-UHFFFAOYSA-N 2-(furan-2-yl)-1,8-naphthyridine Chemical compound C1=COC(C=2N=C3N=CC=CC3=CC=2)=C1 WTMHWTWJFMWWGI-UHFFFAOYSA-N 0.000 description 1
- SKVWGHJCDNDXAG-UHFFFAOYSA-N 2-phenyl-1,8-naphthyridine Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=N2)C2=N1 SKVWGHJCDNDXAG-UHFFFAOYSA-N 0.000 description 1
- UKXDSOBFSYFPBP-UHFFFAOYSA-N 2-pyrazin-2-yl-1,8-naphthyridine Chemical compound c1cnc2nc(ccc2c1)-c1cnccn1 UKXDSOBFSYFPBP-UHFFFAOYSA-N 0.000 description 1
- CZGOOINDASMGQI-UHFFFAOYSA-N 5,6-dihydronaphthalen-1-ol Chemical compound C1CC=CC2=C1C=CC=C2O CZGOOINDASMGQI-UHFFFAOYSA-N 0.000 description 1
- FTERTAJRAQEWBL-UHFFFAOYSA-N C1=CC=C2C(=C1)C=C(S2)C3=NC4=C(C=CC=N4)C=C3 Chemical compound C1=CC=C2C(=C1)C=C(S2)C3=NC4=C(C=CC=N4)C=C3 FTERTAJRAQEWBL-UHFFFAOYSA-N 0.000 description 1
- QIGJMQOGNKJBRW-UHFFFAOYSA-N FC(C1=CC=C(C=C1)C1=NC2=NC=CC=C2C=C1)(F)F Chemical compound FC(C1=CC=C(C=C1)C1=NC2=NC=CC=C2C=C1)(F)F QIGJMQOGNKJBRW-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Description
Claims (3)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910524507.XA CN110272417B (zh) | 2019-06-18 | 2019-06-18 | 2-甲基-1,8-萘啶类化合物及其制备方法与应用 |
PCT/CN2020/089428 WO2020253415A1 (zh) | 2019-06-18 | 2020-05-09 | 2-甲基-1,8-萘啶类化合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910524507.XA CN110272417B (zh) | 2019-06-18 | 2019-06-18 | 2-甲基-1,8-萘啶类化合物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110272417A CN110272417A (zh) | 2019-09-24 |
CN110272417B true CN110272417B (zh) | 2021-07-13 |
Family
ID=67960910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910524507.XA Active CN110272417B (zh) | 2019-06-18 | 2019-06-18 | 2-甲基-1,8-萘啶类化合物及其制备方法与应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110272417B (zh) |
WO (1) | WO2020253415A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110272417B (zh) * | 2019-06-18 | 2021-07-13 | 五邑大学 | 2-甲基-1,8-萘啶类化合物及其制备方法与应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994367A (en) * | 1997-03-07 | 1999-11-30 | The University Of North Carolina At Chapel Hill | Method for treating tumors using 2-aryl-naphthyridin-4-ones |
NZ526450A (en) * | 2000-12-21 | 2005-04-29 | Pliva Istrazivacki Inst D | Macrolide antibiotics |
TW201628622A (zh) * | 2014-11-17 | 2016-08-16 | 製藥公司 | Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合 |
CN105111208B (zh) * | 2015-09-22 | 2018-02-09 | 中国科学院化学研究所 | 一种四氢化1,8‑萘啶类化合物的制备方法及其制得的手性产品 |
CN109678796B (zh) * | 2017-10-19 | 2023-01-10 | 上海长森药业有限公司 | Pd-1/pd-l1小分子抑制剂及其制备方法和用途 |
CN110272417B (zh) * | 2019-06-18 | 2021-07-13 | 五邑大学 | 2-甲基-1,8-萘啶类化合物及其制备方法与应用 |
-
2019
- 2019-06-18 CN CN201910524507.XA patent/CN110272417B/zh active Active
-
2020
- 2020-05-09 WO PCT/CN2020/089428 patent/WO2020253415A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN110272417A (zh) | 2019-09-24 |
WO2020253415A1 (zh) | 2020-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Feng et al. | Gold-catalyzed tandem reaction in water: An efficient and convenient synthesis of fused polycyclic indoles | |
TW201512214A (zh) | 經取代之核苷類似物之立體選擇性合成方法 | |
Łukasik et al. | Simple Synthesis of 2-Aminoaryliminophosphoranes from N-Aryl-2-nitrosoanilines and Their Application in 2-Aminobenzimidazole Synthesis | |
Wang et al. | An improved and benign synthesis of 9, 10-diarylacridine-1, 8-dione and indenoquinoline derivatives from 3-anilino-5, 5-dimethylcyclohex-2-enones, benzaldehydes, and 1, 3-dicarbonyl compounds in an ionic liquid medium | |
CN110156796B (zh) | 异恶唑拼接3,3’-硫代吡咯啉酮双螺环氧化吲哚化合物及其制备方法及应用 | |
Xie et al. | The application of tandem Aza‐Wittig reaction to synthesize artemisinin–guanidine hybrids and their anti‐tumor activity | |
CN114105978A (zh) | 一种氧化吲哚类化合物及其制备方法和应用 | |
Ullah et al. | Synthesis of an isoindoline-annulated, tricyclic sultam library via microwave-assisted, continuous-flow organic synthesis (MACOS) | |
CN104725322B (zh) | 一种2‑胺基嘧啶类化合物及其制备方法 | |
CN110437124B (zh) | 一种吲哚醌衍生物的制备方法 | |
EP3383875B1 (en) | 3-pyrimidinyl pyrrolo [2,3-b] pyridine as anticancer agents and the process for the preparation thereof | |
CN110272417B (zh) | 2-甲基-1,8-萘啶类化合物及其制备方法与应用 | |
CN108503623A (zh) | 一种抑制prmt7的化合物及其制备方法与应用 | |
CN1117733C (zh) | 核苷酸还原酶抑制剂3-ap和3amp的合成方法 | |
CN113105468B (zh) | 一种含苯并吡喃酮的多环螺吲哚酮类化合物及其制备方法和应用 | |
CN112125885A (zh) | 苯并吲哚类双功能分子衍生物及其制备方法与应用 | |
CN109651333A (zh) | 一种具有抗肿瘤活性的2-吲哚-3-基-喹啉类化合物及其制备方法和应用 | |
Tu et al. | An efficient chemoselective synthesis of pyrido [2, 3-d] pyrimidine derivatives under microwave irradiation | |
Zhang et al. | Efficient and Eco-Friendly Procedure for the Synthesis of 2-Amino-4H-Chromenes Catalyzed by Diammonium Hydrogen Phosphate | |
CN109053725B (zh) | 一种2-(四氢喹啉-6-基)-四氢-1,8-萘啶类化合物及其制备方法与应用 | |
CN113105459B (zh) | 一种三唑并嘧啶衍生物及其制备方法和应用 | |
CN112480129B (zh) | 一种含胍基结构单元的多环螺吲哚啉化合物及其制备方法和应用 | |
CN108276420B (zh) | 一种8,13-二氢苯并[5,6]色烯并[2,3-b]吲哚类化合物及其合成方法 | |
Kubelka et al. | A general regioselective approach to 2, 4-disubstituted pyrimidin-5-yl C-2-deoxyribonucleosides | |
Razus et al. | Azulene‐substituted pyridines and pyridinium salts. Synthesis and structure. 1. Azulene‐substituted pyridines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240409 Address after: 529000, 2nd Floor, No.6 Nanchang Village, Encheng Industrial Fourth Road, Enping City, Jiangmen City, Guangdong Province (Information Declaration System) Patentee after: Jiangmen Zhuanyi Information Technology Co.,Ltd. Country or region after: China Address before: No.22, Dongcheng village, Pengjiang district, Jiangmen City, Guangdong Province Patentee before: WUYI University Country or region before: China |